- In April 2023, Telix Pharmaceuticals Limited, a global leader in radiopharmaceutical development, received regulatory approval in the United States for Illuccix, its prostate cancer imaging agent based on Ga-68-PSMA. This milestone underscores Telix’s commitment to advancing targeted diagnostics and improving patient outcomes through precision nuclear medicine. The approval enhances access to state-of-the-art PET imaging tools and strengthens the company's presence in the competitive oncology imaging market
- In March 2023, Siemens Healthineers launched its next-generation Biograph Vision Quadra, a long axial field-of-view PET/CT scanner, designed to improve image resolution and speed. Tailored for both clinical and research applications, this innovation enables whole-body dynamic imaging and higher throughput. The development represents Siemens’ ongoing efforts to enhance PET/CT technology for early and accurate disease detection, supporting broader adoption across high-volume diagnostic centers
- In February 2023, GE HealthCare announced a strategic collaboration with Spectrum Dynamics Medical to integrate its AI-powered molecular imaging solutions into next-generation SPECT and PET systems. This partnership aims to deliver enhanced image quality and automated workflows, accelerating diagnostic processes and improving operational efficiency. The initiative demonstrates GE HealthCare's strategic focus on digital innovation and AI integration in nuclear medicine
- In January 2023, Curium, a leading provider of nuclear medicine solutions, expanded its production capacity for F-18 radiopharmaceuticals in Europe with the inauguration of a new facility in France. This move addresses the growing demand for PET imaging agents and strengthens Curium’s supply chain resilience across the continent. The expansion highlights the company’s commitment to supporting the increasing clinical need for high-quality diagnostic tracers in oncology and neurology
- In January 2023, Bayer AG announced new investments in its theranostics pipeline, emphasizing its focus on combining targeted radiopharmaceutical therapy with diagnostic imaging using PET. The company’s expanding oncology portfolio now includes novel compounds aimed at treating prostate and other solid tumors. This strategic development reflects Bayer’s intent to become a leader in precision oncology through the convergence of therapeutic and diagnostic nuclear medicine technologies
